MYC and hepatocellular carcinoma: Importantly, we found that SGC707 treatment dramatically enhanced the efficacy of anti-PD1 therapy in the Myc/Trp53−/− spontaneous HCC model, which displays de novo resistance to anti-PD1 therapy, as reflected by a significant reduction in tumor volume (Fig. 8N, O).